Prospective Cohort for Early Detection of Liver Cancer

Hepatocellular Carcinoma Clinical Trial

— Pearl  

Official title:

Prospective Cohort for Early Detection of Liver Cancer

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05541601
• Other study ID #: Pearl
• Status: Recruiting
• Start date: February 23, 2022
• Est. completion date: July 2037

Study information

• Verified date: September 2022
• Source: University of Oxford
• Contact: Study Coordinator
• Email: deliver-pearl[@]ndm.ox.ac.uk
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This study aims to recruit 3000 people with liver cirrhosis into a Prospective cohort for early detection of Liver cancer - the Pearl cohort. The study team believe that using a combination of novel tests may improve the detection of early Hepatocellular Carcinoma (HCC).

Description:

During a four-year follow-up period, around 100 Pearl patients are expected to be diagnosed with HCC. Blood, urine, clinical and imaging data will be collected over the follow up period. The samples will be used to identify a range of tests (including genetic, protein and other biomarkers), which along with the clinical data will hopefully identify those most at risk of developing HCC, and to identify HCC at the earliest possible time points.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 3000
• Est. completion date: July 2037
• Est. primary completion date: July 2037
• Gender: All
• Age group: 18 Years to 100 Years

Eligibility

Inclusion Criteria:

1. Patients of all genders, age >18 years

2. Participant is willing and able to give informed consent for participation in the study.

3. Evidence of cirrhosis CP A or B (as defined below, cirrhosis ever diagnosed), with an underlying aetiology of at least one of the following: chronic Hepatitis B Virus (HBV) infection, chronic Hepatitis C Virus (HCV) infection, alcoholic liver disease, non-alcoholic fatty liver disease or haemochromatosis

Cirrhosis Diagnosis Definition

1. Histological assessment (Ishak stage 5 or 6) or

2. At least one of the following:

i. Validated non-invasive marker of fibrosis including fibroscan, AST to Platelet Ratio Index (APRI) score >2 or Enhanced Liver Fibrosis (ELF) score >10.48 or Fibrotest score >0.73. Fibroscan readings should be assessed by aetiology as below:

• HBV: >=10 kPa

• HCV: >=14.5 kPa

• Alcoholic Liver Disease (ALD): >=19.5 kPa

• Non-alcoholic fatty liver disease (NAFLD): >=15 kPa

• Haemochromatosis: >=12kPa ii. Evidence of varices at endoscopy or imaging in the context of a patent portal vein iii. Definitive radiological evidence of cirrhosis (i.e. nodularity of liver and splenomegaly on Ultrasound/CT)

Exclusion Criteria:

1. Diagnosis of current OR historical hepatocellular carcinoma

2. Liver transplant recipients or patients on active listing for liver transplantation

3. Child-Pugh C cirrhosis

4. In the view of the clinician, if the patient has a co-morbidity likely to lead to death within the following 12 months

5. In the view of the clinician, if the patient was not thought to be suitable for HCC surveillance

Related Conditions & MeSH terms

• Carcinoma, Hepatocellular
• Cirrhosis
• Hepatocellular Carcinoma
• Liver Neoplasms

Intervention

Other:
• Blood and Urine samples
The samples will be used to identify a range of tests (including genetic, protein and other biomarkers), which along with the clinical data will hopefully identify those most at risk of developing HCC, and to identify HCC at the earliest possible time points.

Locations

Country	Name	City	State
United Kingdom	Hepatology Clinical Trial Unit, John Radcliffe Hospital	Oxford	Oxfordshire

Sponsors (7)

Lead Sponsor	Collaborator
University of Oxford	Cancer Research UK, Glasgow Caledonian University, OncImmune Ltd, Perspectum, Roche Diagnostic Ltd., University of Nottingham

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Sensitivity of novel diagnostic approaches for the early diagnosis of HCC in enrolled patients who are diagnosed with HCC by conventional approaches.	Diagnostic approaches to be tested will include: detection of epigenetic (e.g. methylation profiling) and genetic mutations, and copy number variations in circulating tumour DNA; multiparametric MRI liver imaging including MR biomarkers of inflammation, fibrosis, fat and iron content; host genetic makeup (relevant variants identified through Genome Wide Association Studies); detection of autoantibodies to tumour associated antigens; epitope mapping of circulating antibody repertoire using random peptide libraries; protein biomarkers including the L3 isoform of alphafetoprotein, and des-gammacarboxy- prothrombin; proteomic and metabolomic profiling, including steroid metabolic signatures in urine.	When 50 cases of HCC have accumulated through to study completion; up to 5 years
Primary	Specificity of novel diagnostic approaches for the early diagnosis of HCC in enrolled patients who are diagnosed with HCC by conventional approaches.	Diagnostic approaches to be tested will include: detection of epigenetic (e.g. methylation profiling) and genetic mutations, and copy number variations in circulating tumour DNA; multiparametric MRI liver imaging including MR biomarkers of inflammation, fibrosis, fat and iron content; host genetic makeup (relevant variants identified through Genome Wide Association Studies); detection of autoantibodies to tumour associated antigens; epitope mapping of circulating antibody repertoire using random peptide libraries; protein biomarkers including the L3 isoform of alphafetoprotein, and des-gammacarboxy- prothrombin; proteomic and metabolomic profiling, including steroid metabolic signatures in urine.	When 50 cases of HCC have accumulated through to study completion; up to 5 years
Primary	Positive/Negative predictive values of novel diagnostic approaches for the early diagnosis of HCC in enrolled patients who are diagnosed with HCC by conventional approaches.	Diagnostic approaches to be tested will include: detection of epigenetic (e.g. methylation profiling) and genetic mutations, and copy number variations in circulating tumour DNA; multiparametric MRI liver imaging including MR biomarkers of inflammation, fibrosis, fat and iron content; host genetic makeup (relevant variants identified through Genome Wide Association Studies); detection of autoantibodies to tumour associated antigens; epitope mapping of circulating antibody repertoire using random peptide libraries; protein biomarkers including the L3 isoform of alphafetoprotein, and des-gammacarboxy- prothrombin; proteomic and metabolomic profiling, including steroid metabolic signatures in urine.	When 50 cases of HCC have accumulated through to study completion; up to 5 years
Secondary	To develop models that can be used to "risk-stratify" cirrhosis patients according to their future risk of HCC	The Harrell's Concordance Index (C-index) will be calculated for each biomarker/model of interest. The minimum and maximum C-index scores are 0 and 1, respectively, where the higher the score the better the biomarker/model is at identifying HCC risk. C-index values indicate the degree to which individuals who develop HCC have a higher risk score than those who do not. C-index values will be adapted to incorporate non-HCC mortality as a competing risk. The C-index value will be used to identify the biomarkers/models with the best discriminative ability.	Throughout study to completion; 5 years
Secondary	To better understand the incidence of HCC in a UK population stratified by underlying cirrhosis aetiology	Cumulative incidence of HCC according to cirrhosis aetiology	At 1, 3 and 5 year post- baseline.

External Links

•   DeLIVER Project Website